Atossa Therapeutics General and Administrative Expenses 2011-2026 | ATOS

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Atossa Therapeutics

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
14 M	12.6 M	11.3 M	8 M	10.6 M	7.22 M	4.86 M	6.48 M	8.85 M	8.63 M	8.56 M	5.02 M	3.17 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
14 M	3.17 M	8.41 M

Quarterly General and Administrative Expenses Atossa Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
3.88 M	3.54 M	3.26 M	-	2.97 M	3.55 M	3.23 M	-	3 M	4.09 M	3.59 M	-	3.04 M	3.16 M	3.25 M	-	2.95 M	3.2 M	2.15 M	-	1.85 M	2.28 M	2 M	-	1.61 M	4.67 M	2.61 M	-	1.89 M	2.67 M	1.4 M	-	1.31 M	1.07 M	1.16 M	-	1.47 M	1.55 M	2.18 M	-	2.4 M	2.45 M	2.36 M	-	2.04 M	2.46 M	1.77 M	-	2.86 M	2.18 M	1.56 M	-	590 K	704 K	601 K	-	-1.27 M	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
4.67 M	-1.27 M	2.31 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Assembly Biosciences ASMB	19.6 M	$ 28.46	3.45 %	$ 319 M	USA
Ascendis Pharma A/S ASND	160 M	$ 221.88	-0.87 %	$ 5 B	Danmark
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Axsome Therapeutics AXSM	63.3 M	$ 156.92	-1.23 %	$ 7.81 B	USA
Galera Therapeutics GRTX	5.69 M	-	-32.59 %	$ 7.61 M	USA
Pharming Group N.V. PHAR	11.7 M	$ 15.36	-0.71 %	$ 7.59 B	Niderland
Autolus Therapeutics plc AUTL	46.7 M	$ 1.37	-4.2 %	$ 350 M	Britain
Kamada Ltd. KMDA	12.6 M	$ 8.5	-1.39 %	$ 260 M	Israel
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
Benitec Biopharma BNTC	6.97 M	$ 10.98	-4.52 %	$ 452 M	USA
Inventiva S.A. IVA	11.2 M	$ 5.78	-4.3 %	$ 138 M	France
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
Compugen Ltd. CGEN	10.9 M	$ 2.09	-0.95 %	$ 195 M	Israel
Tiziana Life Sciences PLC TLSA	286 K	$ 1.21	-3.97 %	$ 71.5 M	Britain
ARCA biopharma ABIO	13.1 M	-	1052.0 %	$ 415 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
PainReform Ltd. PRFX	124 K	$ 2.28	-0.44 %	$ 1.03 M	Israel
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	7.17 M	-	4.01 %	$ 150 M	Canada
Foghorn Therapeutics FHTX	27.6 M	$ 5.0	2.25 %	$ 315 M	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	12.7 M	-	2.71 %	$ 14 M	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
AbCellera Biologics ABCL	83.2 M	$ 3.4	-3.68 %	$ 1.02 B	Canada
BioMarin Pharmaceutical BMRN	1.15 B	$ 54.13	-1.64 %	$ 10.4 B	USA
Curis CRIS	16.8 M	$ 0.77	1.89 %	$ 4.86 M	USA
Bellerophon Therapeutics BLPH	6.02 M	-	-74.18 %	$ 955 K	USA
AgeX Therapeutics AGE	9.33 M	-	-10.17 %	$ 12.2 K	USA
Coherus BioSciences CHRS	101 M	$ 1.52	-5.59 %	$ 178 M	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Burford Capital Limited BUR	99.3 M	$ 7.7	-5.87 %	$ 1.29 B	Britain
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Cellectis S.A. CLLS	37.9 M	$ 3.34	-4.02 %	$ 116 M	France
Arbutus Biopharma Corporation ABUS	22.5 M	$ 4.24	-2.97 %	$ 704 M	Canada
Akouos AKUS	22.2 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	69.6 M	-	-0.23 %	$ 916 M	USA
AIkido Pharma AIKI	29.7 M	-	1.93 %	$ 17.4 M	USA
Cardiff Oncology CRDF	14.2 M	$ 1.8	-1.1 %	$ 120 M	USA
Allakos ALLK	45.1 M	-	-	$ 28.6 M	USA
Cabaletta Bio CABA	19.2 M	$ 2.94	-3.29 %	$ 3.43 M	USA
Iterum Therapeutics ITRM	7.98 M	$ 0.16	-5.45 %	$ 3.15 M	Irlanda
Brickell Biotech BBI	11.2 M	-	-5.38 %	$ 6.06 M	USA
Allena Pharmaceuticals ALNA	12.7 M	-	3.16 %	$ 1.9 M	USA